This issue’s cover features work by Adrian M. Seifert & team on Nectin-4’s connection to poor outcome and immune suppression in patients with PDAC, and targeting Nectin-4 with the antibody-drug conjugate enfortumab vedotin inhibited tumor growth in PDAC organoids:
The cover image shows high Nectin-4 immunohistochemistry staining (brown) in human PDAC.
1Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
2National Center for Tumor Diseases (NCT), Dresden, Germany.
3German Cancer Research Center (DKFZ), Heidelberg, Germany.